COVID-19: A trigger of autoimmune diseases

Cell Biol Int. 2023 May;47(5):848-858. doi: 10.1002/cbin.11997. Epub 2023 Feb 5.

Abstract

The SARS-coronavirus-2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19), has spread worldwide and caused a global health emergency. SARS-CoV-2 is a coronaviridae virus that infects target cells by interacting with the plasma membrane-expressed angiotensin-converting enzyme 2 (ACE2) via the S1 component of the S protein. Effective host immune response to SARS-CoV-2 infection, which includes both innate and adaptive immunity, is critical for virus management and elimination. The intensity and outcome of COVID-19 may be related to an overabundance of pro-inflammatory cytokines, which results in a "cytokine storm" and acute respiratory distress syndrome. After SARS-CoV-2 infection, the immune system's hyperactivity and production of autoantibodies may result in autoimmune diseases such as autoimmune hemolytic anemia, autoimmune thrombocytopenia, Guillain-Barré syndrome, vasculitis, multiple sclerosis, pro-thrombotic state, and diffuse coagulopathy, as well as certain autoinflammatory conditions such as Kawasaki disease in children. We have reviewed the association between COVID-19 and autoimmune disorders in this article.

Keywords: COVID-19; SARS-CoV-2; autoantibody; autoimmune diseases; autoimmunity.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases*
  • COVID-19*
  • Child
  • Cytokines
  • Humans
  • SARS-CoV-2

Substances

  • Cytokines